ES2247377T3 - Medicamento que contiene un efector del metabolismo del glutation (amborxol) junto con acido alfa-lipoico para el tratamiento de la diabetes mellitus. - Google Patents

Medicamento que contiene un efector del metabolismo del glutation (amborxol) junto con acido alfa-lipoico para el tratamiento de la diabetes mellitus.

Info

Publication number
ES2247377T3
ES2247377T3 ES02774028T ES02774028T ES2247377T3 ES 2247377 T3 ES2247377 T3 ES 2247377T3 ES 02774028 T ES02774028 T ES 02774028T ES 02774028 T ES02774028 T ES 02774028T ES 2247377 T3 ES2247377 T3 ES 2247377T3
Authority
ES
Spain
Prior art keywords
acid
lipoic
thiol
ambroxol
lipoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02774028T
Other languages
English (en)
Spanish (es)
Inventor
Michael Tager
Siegfried Ansorge
Gerhard Fries
Dieter Koegst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IMTM GmbH
Z&Z Service GmbH
Original Assignee
Esparma GmbH
IMTM GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esparma GmbH, IMTM GmbH filed Critical Esparma GmbH
Application granted granted Critical
Publication of ES2247377T3 publication Critical patent/ES2247377T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES02774028T 2001-05-28 2002-05-27 Medicamento que contiene un efector del metabolismo del glutation (amborxol) junto con acido alfa-lipoico para el tratamiento de la diabetes mellitus. Expired - Lifetime ES2247377T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10125882 2001-05-28
DE10125882A DE10125882B4 (de) 2001-05-28 2001-05-28 Arzneimittel enthaltend Ambroxol, dessen Salze und/oder Prodrugs zusammen mit α-Liponsäure im Rahmen der Behandlung des Diabetes mellitus

Publications (1)

Publication Number Publication Date
ES2247377T3 true ES2247377T3 (es) 2006-03-01

Family

ID=7686361

Family Applications (2)

Application Number Title Priority Date Filing Date
ES02774028T Expired - Lifetime ES2247377T3 (es) 2001-05-28 2002-05-27 Medicamento que contiene un efector del metabolismo del glutation (amborxol) junto con acido alfa-lipoico para el tratamiento de la diabetes mellitus.
ES04027492T Expired - Lifetime ES2322257T3 (es) 2001-05-28 2002-05-27 Uso de al menos un efector del metabolismo del glutation, junto con acido alfa-lipoico, para el tratamiento inmunomodulador, potenciador de las defensas y/o antiinflamatorio.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES04027492T Expired - Lifetime ES2322257T3 (es) 2001-05-28 2002-05-27 Uso de al menos un efector del metabolismo del glutation, junto con acido alfa-lipoico, para el tratamiento inmunomodulador, potenciador de las defensas y/o antiinflamatorio.

Country Status (9)

Country Link
US (1) US7429614B2 (enExample)
EP (2) EP1529529B1 (enExample)
JP (1) JP4746258B2 (enExample)
AT (2) ATE429911T1 (enExample)
AU (1) AU2002344178A1 (enExample)
DE (3) DE10125882B4 (enExample)
ES (2) ES2247377T3 (enExample)
PT (1) PT1529529E (enExample)
WO (1) WO2002096398A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303229B4 (de) 2003-01-28 2007-07-26 Keyneurotek Ag Ambroxol und Inhibitoren des Angiotensin Converting-Enzyms (ACE) umfassende Arzneimittel Arzneimittel-Zubereitung und ihre Verwendung zur Behandlung von neurodegenerativen Erkrankungen
DE10360954B3 (de) * 2003-12-23 2005-08-18 Esparma Gmbh Verwendung von Silibinin, dessen Salzen und/oder dessen Prodrugs zusammen mit α-Liponsäure zur Behandlung chronisch obstruktiver Lungenerkrankungen
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
JP5785355B2 (ja) * 2004-11-24 2015-09-30 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 動物における生体異物物質の肝臓クリアランスを改良する方法
US20100099751A1 (en) * 2008-10-21 2010-04-22 Al-Mulla Fahd Method of treating diabetes-related vascular complications
KR20110103987A (ko) * 2008-12-01 2011-09-21 인베이스크 테라퓨틱, 인크. 레닌-안지오텐신 알도스테론계 억제제 및 리포산 화합물을 포함하는 조성물, 및 레닌-안지오텐신 알도스테론계 관련 질환의 치료를 위한 이의 용도
CN113244265B (zh) * 2021-03-23 2023-07-14 武汉广行科学研究有限公司 配体修饰的硫化锌纳米粒子、制备方法及其在治疗中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03169813A (ja) * 1989-11-09 1991-07-23 Asta Pharma Ag 細胞保護作用を有する疼痛及び炎症性疾患及び／又はレトロウイルスに起因する病気の治療用医薬並びにその製法
DE4218572A1 (de) * 1992-06-05 1993-12-09 Asta Medica Ag Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
DE4343593C2 (de) * 1993-12-21 1998-05-20 Asta Medica Ag Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz
DE4420102A1 (de) * 1994-06-09 1995-12-14 Asta Medica Ag Arzneimittelkombinationen aus alpha-Liponsäure und herz-kreislaufaktiven Substanzen
GB9715444D0 (en) * 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
US6133304A (en) * 1997-12-23 2000-10-17 Warner-Lambert Company ACE inhibitor-MMP inhibitor combinations
DE19806354B4 (de) * 1998-02-10 2004-09-16 Bdd Group Holding Ag Verwendung von α-Liponsäure oder deren physiologisch verträgliche Salze zur Behandlung von LDL-Hypercholesterinämie
JP2000309543A (ja) * 1999-04-28 2000-11-07 Ajinomoto Co Inc 抗糖尿病剤
DE10125883A1 (de) * 2001-05-28 2002-12-12 Serumwerk Bernburg Ag Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Nierenersatztherapie

Also Published As

Publication number Publication date
ES2322257T3 (es) 2009-06-18
DE10125882A1 (de) 2002-12-12
JP2004531567A (ja) 2004-10-14
WO2002096398A3 (de) 2003-02-27
EP1392288A2 (de) 2004-03-03
AU2002344178A1 (en) 2002-12-09
DE50204093D1 (de) 2005-10-06
ATE429911T1 (de) 2009-05-15
EP1529529B1 (de) 2009-04-29
ATE303145T1 (de) 2005-09-15
DE10125882B4 (de) 2007-03-29
US20040138311A1 (en) 2004-07-15
PT1529529E (pt) 2009-05-11
JP4746258B2 (ja) 2011-08-10
DE50213511D1 (de) 2009-06-10
EP1529529A1 (de) 2005-05-11
EP1392288B1 (de) 2005-08-31
US7429614B2 (en) 2008-09-30
WO2002096398A2 (de) 2002-12-05

Similar Documents

Publication Publication Date Title
Abdelkader et al. Age-related cataract and drug therapy: opportunities and challenges for topical antioxidant delivery to the lens
ES2217313T3 (es) Bencenosulfonamidas o sulfonilureas de 4-(2-(n-(-2-carboxamidoindol)aminoetilo) como antagonistas del pdfg.
May Vitamin C transport and its role in the central nervous system
ES2354976T3 (es) Fosfatasa alcalina placentaria para controlar la diabetes.
CA2427430A1 (en) Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
ES2247377T3 (es) Medicamento que contiene un efector del metabolismo del glutation (amborxol) junto con acido alfa-lipoico para el tratamiento de la diabetes mellitus.
US9101579B2 (en) Inhibition of drug resistant cancer cells
CA2446673C (en) Medicament containing an effector of the glutathione metabolism together with alpha-lipoic acid for use in kidney replacement therapy
AU2020279003B2 (en) Oxathiazin compounds for inhibiting GAPDH
US20040219207A1 (en) Drug preparation comprising alpha-lipoic acid, ambroxol and/or inhibitors of the angiotensin-converting enzyme (ACE) and its use for the treatment of neurodegenerative diseases
Langoth et al. Development of a mucoadhesive and permeation enhancing buccal delivery system for PACAP (pituitary adenylate cyclase-activating polypeptide)
Chemuturi et al. The role of xenobiotic transporters in ophthalmic drug delivery
WO2006110299A1 (en) 3,3'-diindolylmethane compositions inhibit angiogenesis
ES2475211T3 (es) N-acetil-taurinato de cinc para su uso en un método de prevención y/o de tratamiento de enfermedades asociadas con la acumulación de lipofuscina
HK1063606B (en) Medicament containing an effector of the glutathione metabolism together with alpha-lipoic acid for use in kidney replacement therapy
ES2294567T3 (es) Uso de silibinina con acido alfa-lipoico para el tratamiento de enfermedades pulmonares obstructivas cronicas.
Huang et al. Harmine attenuates renal fibrosis via Twist1 suppression: A novel anti-fibrotic strategy for chronic kidney disease with efficacy/safety profiling
WO2022109465A1 (en) Antiviral therapeutic compounds and compositions for use in treatment of coronavirus and influenza virus
WO2012140298A1 (es) Uso de la yessotoxina y sus derivados para el tratamiento y/o la prevención de enfermedades metabólicas
DE10255861A1 (de) Gegen Hepatitis C-Virusinfektionen nützliche Verbindungen und Substanzen